Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Urogen Pharma (URGN : NSDQ)

• Company Description    UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. Number of Employees: 291

• Price / Volume Information    Yesterday's Closing Price: $43.81 Daily Weekly Monthly 20 Day Moving Average: 832,880 shares Shares Outstanding: 48.88 (millions) Market Capitalization: $2,141.70 (millions) Beta: 1.57 52 Week High: $50.81 52 Week Low: $15.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.99% -6.33% 12 Week 37.14% 34.24% Year To Date 87.08% 66.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 400 Alexander Park Drive - Princeton,NJ 08540 USA ph: 646-768-9780 fax: - vincent.perrone@urogen.com http://www.urogen.com

• General Corporate Information    Officers Elizabeth Barrett - Chief Executive Officer and President Arie Belldegrun - Chair Chris Degnan - Chief Financial Officer Cynthia Butitta - Director Leana S. Wen - Director Peer Information Urogen Pharma (CORR.) Urogen Pharma (RSPI) Urogen Pharma (CGXP) Urogen Pharma (BGEN) Urogen Pharma (GTBP) Urogen Pharma (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M96088105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 48.88 Most Recent Split Date: (:1) Beta: 1.57 Market Capitalization: $2,141.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 11.35 EPS Growth vs. Year Ago Period: 73.33% vs. Previous Quarter: 40.43% Sales Growth vs. Year Ago Period: 199.22% vs. Previous Quarter: 42.18% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - -43.79 03/31/26 - -62.85 12/31/25 - -72.93 Current Ratio 06/30/26 - 3.80 03/31/26 - 4.69 12/31/25 - 4.01 Quick Ratio 06/30/26 - 3.41 03/31/26 - 4.28 12/31/25 - 3.65 Operating Margin 06/30/26 - -51.73 03/31/26 - -94.83 12/31/25 - -139.81 Net Margin 06/30/26 - -51.73 03/31/26 - -94.83 12/31/25 - -139.81 Pre-Tax Margin 06/30/26 - -51.98 03/31/26 - -98.45 12/31/25 - -139.74 Book Value 06/30/26 - -2.71 03/31/26 - -2.55 12/31/25 - -2.25 Inventory Turnover 06/30/26 - 0.98 03/31/26 - 1.08 12/31/25 - 1.26 Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©